COMMUNIQUÉS West-GlobeNewswire

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
09/07/2026
Cohort 1 Topline Data Expected in the Second Week of September 2026 RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a [...]
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
09/07/2026
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin [...]
What Clinicians Ask About Cartilage Regeneration Supplements: Answering the Clinical Questions Around Cartigenix HP®
09/07/2026
Three published human studies covering more than 1,700 participants provide peer-reviewed answers to the clinical questions most frequently raised about cartilage regeneration supplementation*† SCOTTSDALE, AZ, July 09, [...]
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care
09/07/2026
SHANGHAI, July 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has been named to the KPMG China Healthcare 50 list, [...]
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
09/07/2026
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a [...]
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
09/07/2026
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
09/07/2026
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachment ATSN-401 advancing in IND-enabling studies [...]
Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
09/07/2026
ORANGE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its second quarter 2026 financial results on Thursday, July 30, 2026, after market close. Following the release, [...]
UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery
09/07/2026
ESSEN, July 09, 2026 (GLOBE NEWSWIRE) -- Smart wellness innovator UREVO has been named a winner of the Red Dot Award: Product Design 2026 in the Innovative Design category for its AI-Powered Wireless Recovery Boots . [...]
Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
09/07/2026
Tris Pharma’s Wholly-Owned Subsidiary is Advancing the Development of Cebranopadol as it Prepares for New Drug Application (NDA) Submission Later This Year MONMOUTH JUNCTION, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- [...]
NTG Nordic Transport Group A/S - H1 2026 Conference Call
09/07/2026
NTG Nordic Transport Group A/S – H1 2026 Conference Call We expect to release the H1 2026 interim results of NTG Nordic Transport Group on the evening of August 10, 2026. A webcast and conference call will be held in [...]
Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.
09/07/2026
Dysport ® a obtenu des résultats préliminaires statistiquement significatifs de phase III, atteignant les critères d’évaluation principaux dans la migraine épisodique (E-BEOND) et dans la migraine chronique (C-BEOND) [...]
Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges
09/07/2026
A new peer-reviewed study validates CellEDIT’s ability to overcome cell-editing barriers, uncovering dermokine’s pivotal role in wound healing and skin cancer biology. Zurich, Switzerland – July 9, 2026 – Cytosurge AG, [...]
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
09/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative [...]
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
09/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative [...]
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
09/07/2026
Dysport ® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to [...]
Roche receives CE Mark for blood test to identify tuberculosis infection
09/07/2026
The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets. Performed on Roche’s industry-leading and widely available [...]
Outliyr's Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
09/07/2026
Outliyr's free public database catalogs more than seventy red light therapy panels and other light therapy devices, and publishes its own spectrometer measurements next to manufacturer claims for the units it has tested [...]
Cascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMD
08/07/2026
PORTLAND, Ore. and ENSCHEDE, The Netherlands, July 08, 2026 (GLOBE NEWSWIRE) -- Cascade Prodrug Inc. and Uneedle are advancing their collaboration to evaluate CPD100, Cascade’s first-in-class hypoxia-targeted [...]

Pages